Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE

By sjmartinez • May 29, 2023

Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023 May 29. doi: 10.1111/bjh.18883. Epub ahead of print. PMID: 37246588.

Tags: chronic phase chronic myeloid leukaemia, dasatinib, deep molecular response, Hematology/Oncology, major molecular response, Publications, treatment-free remission

PKC inhibitors reveal PKC isoforms involved in HIV latency reversal and immunomodulation

Zaikos TD, Pham V, Chou TC, Moran JA, Turner SR, Yu BH, Hourani R, Ranjan A, Zack JA, Wender PA, Marsden MD. PKC inhibitors reveal[...]

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson[...]